Trabectedin - Latest Advances

Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma.

Journal: Frontiers in cell and developmental biology

Published: July 30, 2025

The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.

Journal: International journal of molecular sciences

Published: July 18, 2025

Maintenance after first-line treatment for advanced soft tissue sarcoma.

Journal: Critical reviews in oncology/hematology

Published: June 26, 2025

Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.

Journal: Therapeutic advances in medical oncology

Published: May 20, 2025

Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review.

Journal: Anti-cancer drugs

Published: May 06, 2025

Correction: Povo-Retana et al. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. Molecules 2024, 29, 331.

Journal: Molecules (Basel, Switzerland)

Published: April 16, 2025

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes.

Journal: Cancer immunology, immunotherapy : CII

Published: April 16, 2025

Exploiting divergent mechanisms of trabectedin for bone tumors.

Journal: Molecular therapy. Oncology

Published: March 28, 2025

Recent advances in the Total synthesis and structural modification of Ecteinascidin-743.

Journal: Bioorganic chemistry

Published: March 25, 2025

First case report of radiation-recall myositis following trabectedin in patient with stage IV mesenchymal chondrosarcoma.

Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Published: March 11, 2025

Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma.

Journal: Minerva endocrinology

Published: February 25, 2025

Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.

Journal: Cancer immunology, immunotherapy : CII

Published: February 19, 2025

Filters

Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma.

Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma.

The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.

The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.

Maintenance after first-line treatment for advanced soft tissue sarcoma.

Maintenance after first-line treatment for advanced soft tissue sarcoma.

Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.

Maintenance therapy-a potential strategy to prolong the survival of advanced soft tissue sarcoma patients.

Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review.

Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review.

Correction: Povo-Retana et al. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. Molecules 2024, 29, 331.

Correction: Povo-Retana et al. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. Molecules 2024, 29, 331.

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes.

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes.

Exploiting divergent mechanisms of trabectedin for bone tumors.

Exploiting divergent mechanisms of trabectedin for bone tumors.

Recent advances in the Total synthesis and structural modification of Ecteinascidin-743.

Recent advances in the Total synthesis and structural modification of Ecteinascidin-743.

First case report of radiation-recall myositis following trabectedin in patient with stage IV mesenchymal chondrosarcoma.

First case report of radiation-recall myositis following trabectedin in patient with stage IV mesenchymal chondrosarcoma.

Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma.

Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma.

Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.

Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.